Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Gets FDA Nod for Human Testing of Ebola Drug

Premium

Tekmira Pharmaceuticals this week announced that it has received clearance from the US Food and Drug Administration to begin human testing of an RNAi-based treatment for Ebola virus infection.

The drug, TKM-Ebola, was added to Tekmira's pipeline last summer after the company reported data showing that a cocktail of modified siRNAs targeting the Zaire Ebola virus L polymerase, viral protein 24, and viral protein 35 could completely protect non-human primates from a lethal dose of the virus when delivered using proprietary lipid nanoparticles (GSN 8/19/2010).

Tekmira, which is developing TKM-Ebola with the support of a $140 million contract from the US government, expects to begin a phase I trial in early 2012.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more